Term
|
Definition
| selective estrogen receptor modifiers (SERMs); complete binding of estrogen |
|
|
Term
|
Definition
|
|
Term
|
Definition
| bicalutamide, fludamide, nilutamide, abiraterone, enzalutamide |
|
|
Term
|
Definition
| anastrozole, letrozole, exemestane |
|
|
Term
|
Definition
| recognized CD20 B Cell specific (non-hodgkins lymphoma, serous infusion rxns) |
|
|
Term
|
Definition
| HER-2 positive breast cancer, blocks HER2 signaling, causes cardiotoxicity |
|
|
Term
|
Definition
| binds vascular endothelial growth factor (VEGF), Metastatic cancer, toxicity: impaired wound healing, GI perforation and HTN |
|
|
Term
|
Definition
| binds epidermal growth factor receptor (EGFR), colorectal head and neck lung |
|
|
Term
|
Definition
| metastatic prostatic cancer, process where you take out own APC cells out, get modified to stimulate T cells, then reinfused to have T cell attack prostate cancer |
|
|
Term
| tyrosine kinase inhibitors |
|
Definition
| the NIBs and that all I am going to say...sorry but he lists five million and Im pissed and I hate this and why did I do pharmacy |
|
|
Term
|
Definition
| BRAF kinase inhibitor, oral for metastatic melanoma with BRAF mutation |
|
|
Term
|
Definition
| mTOR kinase inhibitor, breast pancreatic and renal |
|
|
Term
|
Definition
| hedgehog pathway inhibitor for metastatic basal cell cancer |
|
|
